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The vitamin D endocrine system is involved in a wide variety of biological processes including bone metabolism, modulation of the
immune response, and regulation of cell proliferation and differentiation. Variations in this endocrine system have, thus, been linked to
several common diseases, including osteoarthritis (OA), diabetes, cancer, cardiovascular disease, and tuberculosis. Evidence to support
this pleiotropic character of vitamin D has included epidemiological studies on circulating vitamin D hormone levels, but also genetic
epidemiological studies. Genetic studies provide excellent opportunities to link molecular insights with epidemiological data and have
therefore gained much interest. DNA sequence variations, which occur frequently in the population, are referred to as ‘‘polymorphisms’’
and can have modest and subtle but true biological effects. Their abundance in the human genome as well as their high frequencies in the
human population have made them targets to explain variation in risk of common diseases. Recent studies have indicated many
polymorphisms to exist in the vitamin D receptor (VDR) gene, but the influence of VDR gene polymorphisms on VDR protein function
and signaling is largely unknown. So far, three adjacent restriction fragment length polymorphisms for BsmI, ApaI, and TaqI,
respectively, at the 3V end of the VDR gene have been the most frequently studied. Because these polymorphisms are probably
nonfunctional, linkage disequilibrium with one or more truly functional polymorphisms elsewhere in the VDR gene is assumed to explain
the associations observed. Research is therefore focussed on documenting additional polymorphisms across the VDR gene to verify this
hypothesis and on trying to understand the functional consequences of the variations. Substantial progress has been made that will
deepen our understanding of variability in the vitamin D endocrine system and might find applications in risk assessment of disease and
in predicting response-to-treatment.
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together are major players in the vitamin D endocrine
system. This system plays an important role in skeletal
metabolism, including intestinal calcium absorption, but
has also been shown to play an important role in other
metabolic pathways, such as those involved in the im-
mune response and cancer (Haussler et al., 1998). In the
immune system, for example, vitamin D promotes mono-
cyte differentiation and inhibits lymphocyte proliferation
and secretion of cytokines, such as interleukin 2 (IL2),
interferon-g, and IL12. In several different types of
cancer cells, vitamin D has been shown to have anti-
proliferative effects.
At the same time, it is also widely known that large
interindividual differences exist. One approach to under-
3 http://www.ncbi.nih.gov/mapview/maps.cgi?taxid=9606&chr=12&
maps = gb4,sts&SET = CLOSE&LINKS = ON&VERBOSE = ON&
ZOOM=10&sts=5822.
1 http://www.marshfieldclinic.org/research/genetics.
2 http://www.ncbi.nlm.nih.gov/mapview/maps.cgi?ORG =hum&
MAPS=ideogr,loc&VERBOSE=ON&CHR=12.
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system is to study the influence of variations in the DNA
sequence of important proteins of this system. For example,
deleterious mutations in the VDR gene cause 1,25-dihy-
droxyvitamin D resistant rickets, a rare monogenetic dis-
ease. More subtle sequence variations (polymorphisms) in
the VDR gene occur much more frequently in the popula-
tion, but they have not been systematically analysed and
their effects on VDR function are poorly understood. Their
influence on the vitamin D endocrine system is currently
under scrutiny in relation to a number of so-called complex
diseases and traits, such as osteoporosis. This so-called
candidate gene approach in the genetic dissection of com-
plex traits is currently gaining increased importance over
genome search approaches using linkage analysis (Risch
and Merikangas, 1996).
The interpretation of polymorphic variations in the
VDR gene is severely hindered by the fact that until
now, only few polymorphisms in this large gene have
been studied, and that most of these are anonymous
restriction fragment length polymorphisms (RFLP), i.e.,
have an unknown functional effect. One expects them to
be linked to truly functional polymorphisms elsewhere in
the VDR gene [or in nearby gene(s)] which can then
explain the associations observed. Thus, to understand
the mechanisms underlying the associations, one has to
analyse the genomic organization of the VDR locus, to
identify which genes are present in the chromosomal area,
to categorize all relevant VDR polymorphisms, to deter-
mine the haplotypes across the gene, to determine their
relationship with the RFLP markers used so far, and—
finally—to perform association analyses with relevant
phenotypic endpoints such as disease.
Below we present a more detailed description of the
genomic organization of the VDR gene including discus-
sion on polymorphisms, linkage disequilibrium, and
haplotypes. Historically speaking, studies of VDR poly-
morphisms in relation to bone endpoints, including osteo-
porosis in particular, have received most attention, while
the analysis of VDR polymorphisms in relation to other
diseases, including breast and prostate cancer and immune-
related disorders, has reached the literature somewhat later
on. This allows studies on associations with bone end-
points to be compared to a certain extent and to illustrate
some of the difficulties in interpreting the results. This is
much less possible for VDR polymorphism studies in
relation to other disease endpoints, although similar inter-
pretation problems exist. Essentially, these interpretation
problems find their origin in the lack of knowledge on
which polymorphisms are present in the VDR gene area
and not knowing what the functional relevance is of these
polymorphisms. Therefore, most attention in this review
will be focussed on these aspects rather than providing an
exhaustive review on which studies have found their way
to the literature on VDR polymorphisms and association
with one or other disease endpoint.2. Genomic structure of the 12Q13 locus
After cloning the human VDR cDNA in 1988 by Baker
et al. (1988), it took almost 10 years before major parts of
the genomic structure of the human VDR gene became clear
as described by Miyamoto et al. (1997). All of this hap-
pened of course before the Human Genome Project became
to bear fruit in the form of easily accessible databases where
genomic sequences can be found. Yet, these databases are
still not complete and for particular genes, efforts have to be
made to determine their genomic structure. The location of
the VDR gene on the physical map of chromosome 12 was
elucidated first roughly by linkage mapping by Labuda et al.
(1992) and later on somewhat more refined by fluorescent in
situ hybridization (FISH) and radiation hybrid mapping by
Taymans et al. (1999). However, these studies defined the
position of the VDR gene in very general terms with a
resolution of >100 kb, and this is insufficient for under-
standing the role of VDR polymorphisms in disease. The
major reason to know the exact gene content and distances
of this area is coming from the genetic association studies.
Since mostly anonymous polymorphisms have been used,
one of the explanations of the associations observed is that
not the VDR gene itself is explaining the association but
another nearby gene. It is therefore important to know which
genes are also present in the area, how close they are to the
VDR gene and, thus, how likely it is that these other genes
are explaining the associations.
We have therefore extended these physical mapping
studies of the VDR gene to create a high-resolution
physical map of the chromosomal 12q13 region in which
the VDR gene is located. For this, we applied thorough
analysis of all available databases with genomic sequences,
pulsed field gel electrophoresis to determine the exact
location, and order of the VDR gene and its neighbouring
genes. Our analysis of the genomic organization of the VDR
locus at chromosome 12q13.1 has shown that the VDR
gene itself is quite large (just over 100 kb; see Fig. 1; van
Meurs et al., unpublished), has an extensive promoter
region capable of generating multiple tissue-specific tran-
scripts (Crofts et al., 1998), and lies just downstream from
the collagen type II alpha 1 (COL2A1) gene (Huang et al.,
1991; Takahashi et al., 1990).
On the genetic map1, both VDR and COL2A1 genes are
mapped around position 63 cM, between the markers
D12S85 and D12S368. The radiation hybrid map2 confirms
the close conjunction of the two genes since both genes are
mapped close to the 210 centiRod position. The sequence-
tagged site (STS)-based contig map3 shows that VDR and
Fig. 1. Genomic structure of the VDR-COL2A1 locus on chromosome 12q13.1 and detailed physical map position of the PAC clones 228P16 and 1057I20.
The arrow indicates direction of transcription of the VDR gene. PFK= phosphofructokinase; VATPase =Vacuolar ATPase; SENP1= sentrin/SUMO-specific
protease; HDAC7= histone deacetylase 7.
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and P228P16, respectively). Fig. 1 shows a compilation of
all the information from the databases and our own results
with respect to the VDR-COL2A1 locus combined with
information of the genomic organization of the VDR gene.
Recently, most of this information can also be found in the
draft of the human genome4, but up to now, a gap in the
sequence was still present between COL2A1 and VDR. Fig.
1 shows the completed physical map of the region surround-
ing VDR. Besides already identified genes [phosphofruc-
tokinase (PFKM), sentrin/SUMO specific protease
(SENP1), and histone deacetylase (HDAC7)], also some
so far unknown genes were identified (e.g., a gene-like
structure MGC5576; information available at http://
www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?/=79022).
From these results, it appears that, in the absence of
evidence for the role of the other genes in the area in, for
example, bone metabolism, the VDR gene is the obvious
candidate gene to explain the associations found. The next
step is to determine the polymorphisms in the relevant areas
and determine how they are interacting with each other in
genetic terms and in functional terms.3. VDR polymorphisms
Information on the existence of VDR polymorphisms so
far has come from analysis of only limited areas in the gene
and by using rather insensitive techniques to find polymor-
phisms, such as screening with different restriction enzymes
for polymorphic banding patterns in Southern blot hybrid-
ization experiments. Examples of this include the ApaI-
(Faraco et al., 1989), EcoRV- (Morrison et al., 1992), BsmI-
(Morrison et al., 1992), TaqI- (Morrison et al., 1994), and
Tru9I- (Ye et al., 2000) restriction fragment length poly-
morphisms (RFLPs) discovered at the 3V end of the VDR
gene by this approach in the early 1990s. In Fig. 2, a number
of the currently known VDR polymorphisms are depicted.4 http://genome.ucsc.edu.A special case in this respect is presented by the
discovery of the so-called FokI RFLP. Upon comparison
of the original Baker sequence of the VDR cDNA (Baker et
al., 1988), two potential translation initiation start sites
(ATG) were observed and subsequent sequence compari-
sons have shown that a T to C polymorphism exists (ATG to
ACG) at the first potential start site (Gross et al., 1996; Saijo
et al., 1991; Sturzenbecker et al., 1994). This polymor-
phism, also referred to as the start codon polymorphism or
SCP, was later on defined using the FokI restriction enzyme
in an RFLP test (Arai et al., 1997). Thus, two protein
variants can exist corresponding to the two available start
sites: a long version of the VDR protein (the T-allele or the
‘‘f’’ allele; and also referred to as the M1 form, i.e., the
methionine at first position) and a protein shortened by three
amino acids (the C-allele detected as the ‘‘F’’ allele; also
referred to as the M4 form, i.e., the methionine at fourth
position). Hitherto, this is the only known protein polymor-
phism in the VDR gene.
A more informative approach to find polymorphisms is
to simply determine the base pair sequence of the same part
of the VDR sequence in a number of different individuals.
This was applied by Morrison et al. (1994) for the 3.2 kb 3V
untranslated region (UTR) of the gene when searching for
additional polymorphisms and possible functional variations
to explain an association of bone mineral density (BMD)
differences with the (supposedly nonfunctional) BsmI RFLP.
When they sequenced two subjects, who were homozygous
for the most frequent BsmI–ApaI–TaqI haplotypes (see
below), i.e., BAt–BAt and baT–baT, they reported 13
polymorphisms in 3.2 kb, corresponding to the expected 1
in 300 bp to be variant. Among the sequence differences
they reported was a polyA-tract with a varying number of
A-residues with alleles that vary in length between 12 and
18 adenosines. Durrin et al. (1999) expanded this approach
and sequenced the 3VUTR in five subjects homozygous for
the baT-haplotype and three subjects homozygous for the
BAt-haplotype and, in total, identified seven polymor-
phisms (see Fig. 3) of which four were common and three
were rare in the eight subjects they analysed. Surprisingly,
Fig. 2. Exon– intron structure of the VDR gene and position of known polymorphisms. * indicates that these polymorphisms are in the coding sequence. See
text for further details on the polymorphisms. The 3VUTR polymorphisms are shown in more detail in Fig. 5.
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analyses by Durrin et al. and Morrison et al. When consid-
ering the methods used and the number of subjects analysed,
it seems likely that the polymorphisms reported by Durrin et
al. do not contain sequence errors and seem to be more
accurate. However, the number of subjects analysed is still
limited and they were highly selected, so it is likely that
more as yet uncovered polymorphisms exist in the 3.2 kb
UTR (see below).
A similar sequence comparison approach was followed
by Brown et al. (2000) when they analysed the coding
region of the VDR gene in 59 parathyroid tumours to find
mutations. Apart from the previously reported TaqI- and
FokI-polymorphisms, they reported no polymorphisms in
the coding region and found two intronic polymorphisms
near exons 2 and 8 (shown in Fig. 2).Fig. 3. Structure and position of polymorphisms in the 3VUTR of the VDR gene ba
according to Baker et al. (1988). TGA indicates the stop codon in exon 9 where
identified by Durrin et al. Below, the two most frequent BsmI –ApaI –TaqI haplot
haplotype 2 ( =BAt), and the alleles of the 3VUTR polymorphisms to which
polymorphisms which were identified in both studies.Another VDR polymorphism that was found through
sequence analysis of a targeted area is the so-called Cdx2
polymorphism. Arai et al. (2001) reported a G to A
sequence variation among Japanese women in (what they
thought was) the VDR 1a promoter when characterizing
this promoter area of the VDR gene. The G to A polymor-
phism is in a binding site for an intestinal-specific tran-
scription factor, called Cdx2 (Yamamoto et al., 1999).
Recently, our laboratory has shown the Cdx2 polymor-
phism to be in the VDR 1e promoter (see Fig. 2), to be
present among Caucasians as well as other race groups, and
has developed an allele-specific genotyping assay for it
(Fang et al., 2003).
Currently, it is possible to identify potential polymor-
phisms in silico through bio-informatic approaches by
mining of databases such the NCBI SNP consortiumsed on Morrison et al. (1994) and Durrin et al. (1999). The bp numbering is
the 3VUTR starts. DE I– III refer to the so-called destabilising elements as
ypes across this part of the gene are depicted, i.e., haplotype 1 ( = baT) and
they are linked based on eight subjects analysed. The * indicates the
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the Celera database (http://www.celeradiscoverysystem.
com). Indeed, many polymorphisms are usually reported
in such databases for any gene of interest, but their validity
has to be judged very carefully. For example, for the area
which we analysed in detail for the VDR gene, only 40% of
the polymorphisms currently reported in these databases
turns out to be real (Fang and van Meurs, unpublished).
Although we can expect the databases to improve over time,
for polymorphism finding in the near future, it might
therefore still be necessary to generate reliable sequence
information from multiple individuals.
We have recently conducted such a more comprehen-
sive study of the VDR gene and found 63 polymorphisms
across 22 kb of sequenced parts the VDR gene (Fang et al.,
manuscript in preparation). Apart from the known poly-
morphisms shown in Figs. 2 and 3, a number of novel
polymorphisms were found in the promoter areas includ-
ing in and around exons 1f–1c, in and around exons 2–9,
and in the 3VUTR. We found the majority of polymor-
phisms to be in regulatory areas rather than in coding
exons. Since variation in the protein sequence could
result in drastic functional effects, such as changes in
affinity for the ligand or binding to DNA, it seems more
likely that polymorphic variation and thus population
variance would exist in areas of the gene that regulate
the level of expression, such as the 5V promoter area and
the 3VUTR region.
Once we know which polymorphisms are present in a
certain candidate gene area, it is important to understand
how they relate to each other, i.e., in a genetic sense as
well as in a biologically functional sense. Genetically, we
need to understand which alleles are linked to each other
by studying the linkage disequilibrium between polymor-
phisms. Functionally, we have to determine how certain
combinations of alleles across such a candidate gene
might augment or diminish certain effects on gene
function.4. Linkage disequilibrium and haplotypes
Linkage disequilibrium (LD) measures describe the as-
sociation (or co-occurrence) of alleles of adjacent poly-
morphisms with each other (Wall and Pritchard, 2003).
This means, in practice, that one polymorphism can predict
the other adjacent ‘‘linked’’ one because very little recom-
bination has occurred between them over the time of
evolution and population history. High levels of LD in a
certain area will coincide with a limited number of ‘‘hap-
lotypes’’ in that area. Haplotypes are blocks of linked alleles
of adjacent polymorphisms whereby the length of such a
block coincides with the strength of LD across the area. By
analysis of polymorphisms across 51 autosomal areas in the
human genome, it has become evident that, indeed, such
haplotype blocks exist in the human genome (Gabriel et al.,2002). The haplotype block size can vary between 5 to >50
kb with an average around 10–20 kb. That means that
frequent haplotype alleles can be found that encompass the
polymorphic variation in such areas. In practice, this also
means that relatively few polymorphisms have to be geno-
typed to ‘‘cover’’ the variance in a certain area. Therefore, a
massive effort is currently going on to determine a haplo-
type map of the human genome (Gabriel et al., 2002; The
International HapMap Consortium, 2003; Wall and Pritch-
ard, 2003).
It follows that the LD and haplotype structure of a
certain candidate gene is important for association analyses
to understand how polymorphic variation in such a gene
can contribute to risk of disease and population variance of
certain phenotypes of interest. When a certain allele of a
polymorphism has been found to be associated with—
say—risk of fracture, it follows that this association might
be explained by the effect of this particular allele, but
also—because of LD and the haplotype structure—by one
or more other alleles which happen to be linked to this
allele within the haplotype. Once we know which haplo-
type carries this risk allele, we can determine by cell
biological and molecular biological functional analyses
which of the variants on that haplotype allele truly cause
this effect.
Based on some of the known polymorphisms shown in
Fig. 2, several studies have analysed the extent of linkage
disequilibrium (LD) across the VDR gene. Since these
analyses have used only a small number of polymorphisms,
accurate information on LD and haplotypes so far has been
very limited. Nevertheless, strong LD at the 3V end of the
gene has been observed early on for the BsmI-, ApaI-,
EcoRV-, and TaqI-RFLPs (Morrison et al., 1992, 1994).
This information was taken a step further by our laboratory
to describe molecular haplotypes for these RFLPs (Uitter-
linden et al., 1996). We identified five haplotype alleles in a
large Caucasian population of which haplotypes 1 (baT;
48%) and 2 (BAt; 40%) were the most frequent and
corresponded to the ones identified by Morrison et al.
(1994). In line with this, strong LD was also observed
between the BsmI RFLP and the polyA variable number
of tandem repeat (VNTR) in the 3VUTR (Ingles et al.,
1997). This latter polymorphism has at least 12 different
alleles (in 627 subjects analysed in Ingles et al., 1997 across
five ethnic groups), but the allele size distribution of the
polyA VNTR essentially follows a bimodal distribution.
This pattern is such that this marker can be characterized
as bi-allelic and that subjects can be classified as having
alleles with short or long polyA stretches. Ingles et al.
reported strong linkage between the ‘‘b’’ allele and a long
polyA stretch and the ‘‘B’’allele and a short polyA stretch.
Combined with the results of Morrison et al. (1994), Durrin
et al. (1999), and our results (Uitterlinden et al., 1996), it
follows that the Bsm–Apa–Taq haplotype 1 (baT) is linked
to a large number of ‘‘A’’s in the polyAVNTR (n = 18–24)
while haplotype 2 (BAt) is linked to a smaller number of A’s
A.G. Uitterlinden et al. / Gene 338 (2004) 143–156148(n = 13–17) (see Fig. 3). Interestingly, several studies have
shown that the FokI polymorphism showed no linkage to
any of the other VDR polymorphisms.
Currently, it is important to assess linkage disequilibrium
across other areas, e.g., 5V promoter, and to construct
haplotype maps of the VDR. It is expected that these data
will soon be available.5. Ethnic variation in polymorphisms
VDR polymorphisms have been identified and analysed
so far mostly in Caucasians and, to a lesser extent, in other
ethnic groups. For example, the Cdx2 polymorphism was
discovered in Japanese (Arai et al., 2001) and has only
recently been analysed in Caucasians (Fang et al., 2003).
For the most widely studied VDR polymorphisms, some-
times substantial differences have been noted between races
and/or ethnic groups (see Table 1 and Zmuda et al., 2000).
For example, the f or T allele of the FokI RFLP,
corresponding with the 427 aa long VDR protein variant,
occurs with lower frequency in Africans when compared to
Caucasians and Asians, while the B allele of the BsmI RFLP
has a lower frequency in Asians compared to Caucasians
and Africans. Similarly, Ingles et al. (1997) showed differ-
ences between ethnic groups for the polyA VNTR in the
3VUTR. We have found the frequency of the Cdx2 A allele
to vary widely across different ethnic groups with the A
allele being lowest in Caucasians, at about 19% population
frequency, and highest (74%) in Africans (Fang et al.,
2003).
Why do we see such differences? In general, all poly-
morphisms start as mutations which occur perhaps due to a
DNA damage event, and then can grow in frequency in theTable 1
Comparison of VDR allele frequencies across the three major ethnic groups
for the most widely studied polymorphismsa
VDR polymorphism Minor alelleb Ethnic group (%)
Caucasian Asian African
Individual polymorphisms
Cdx2 A 19 43 74
FokI ffT 34 51 24
BsmI B 42 7 36
ApaI A 44 74 31
TaqI T 43 8 31
polyA short n= 13–17 41 12 29
Bsm-Apa-Taq haplotypes
baT : haplotype 1 43 75 26
BAt : haplotype 2 39 7 16
bAT: haplotype 3 11 17 59
a Data are from various sources (Arai et al., 1997; Durrin et al., 1999;
Fang et al., 2003; Faraco et al., 1989; Gross et al., 1996; Ingles et al., 1997;
Morrison et al., 1992; Morrison et al., 1994; Saijo et al., 1991;
Sturzenbecker et al., 1994; Uitterlinden et al., 1996; Ye et al., 2000) and
from Fang et al. (manuscript in preparation).
b Minor allele in Caucasians; see text for details on definition of alleles.population and become true polymorphisms. Thus, allele
frequency differences between ethnic groups most likely
result from evolutionary processes and population genetic
behaviour. The same holds true for the LD between the
polymorphisms and the haplotype structure. Table 1 shows
the frequencies of the Bsm–Apa–Taq haplotypes which we
have recently determined in different ethnic groups (Fang et
al., manuscript in preparation). They show complex patterns
across ethnic groups which cannot be derived from the
frequency differences of the individual composite polymor-
phisms. This is probably due to the existence of different
sets of alleles linked together to form haplotypes across the
3V end of the VDR gene. In other words, the haplotype ‘‘1’’
(or baT) in Caucasians is not defining the same set of linked
alleles as the haplotype 1 in Asians or Africans. The set of
haplotypes will reflect the out-of-Africa theory describing
the origin of human populations across the globe and
perhaps also will be due to gene–environment interactions
in which certain variants might have had survival and/or
reproductive advantages. One can assume that relatively
‘‘old’’ polymorphisms show little variation between differ-
ent ethnic groups whereas relatively new polymorphisms
might display large differences. In this respect, for example,
the Cdx2 polymorphism appears relatively new and the FokI
RFLP rather old.
For the interpretation of association studies, we can
assume that individual functional polymorphisms might
have the same functional effect in different ethnic groups
because the physiological role of the vitamin D endocrine
system will not be vastly different between ethnic groups.
However, the individual polymorphisms will explain more
or less the population variance given their difference in
frequency between these ethnic groups. This is also the
basis to for interpretation of ecological studies where allele
frequencies across (ethnic) groups are correlated with the
different incidence of disease/phenotype between such
groups. For nonfunctional or anonymous polymorphisms,
the situation is different because here, we rely on the LD
that is detected by the polymorphism to explain its associ-
ation with a disease. Moreover, as shown for the Bsm–
Apa–Taq haplotypes in Table 1, the frequencies of these
‘‘marker haplotypes’’ (consisting of nonfunctional polymor-
phisms which are markers for truly functional alleles else-
where) are very different between ethnic groups. More
importantly, as discussed above, the particular alleles that
will be linked in the individual haplotypes are likely to be
very different. Thus, if, for example, haplotype 1 is found
associated in Caucasians and also in Africans, this can be
due to linkage with a totally different functional allele.
Alternatively, if an association of such a marker-haplotype
is seen in Caucasians but, for example, not in Asians, this
can be explained because the LD between the marker and
the functional allele is different between these groups. This
further emphasizes the absolute necessity to construct hap-
lotype maps across the VDR as mentioned in the previous
section.
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consequences of ethnic allele variation, also because of
the vastly different environmental factors between ethnic
groups, such as diet and exercise. In addition, there are very
different ‘‘genetic backgrounds’’ (i.e., the remainder of the
genome and genetic variation therein) between ethnic
groups in which these VDR polymorphisms interact with
each other and with other genetic variants of other genes. It
is therefore important to start by defining the haplotype
structure of VDR polymorphisms in different ethnic groups.
This will reveal which VDR alleles occur together on certain
haplotypes and what their frequency is in different ethnic
groups. Subsequently, together with the information on
differences in environmental factors between ethnic groups,
we can start to understand the relevant gene–environment
interactions.
Fig. 4. Schematic depiction of the different organizational levels in
physiology which determine the relation between a DNA polymorphism
and the association with an endpoint in an epidemiological study, which are
at the same time the levels at which functionality of VDR polymorphisms
can be determined. Such functionality can be established using different
types of readouts of test systems indicated on the right of the arrow. OC
VDRE= osteocalcin vitamin D responsive element. PBMC= peripheral
blood mononuclear cell.6. Functionality of polymorphisms
The interpretation of the association studies using VDR
polymorphisms is severely hindered by the fact that most
of the polymorphisms used are anonymous. The likely
explanation for any observed association is then to assume
the presence of a truly functional sequence variation
elsewhere in the gene which is—to a certain extent—in
linkage with an allele of the anonymous polymorphism
used. As can be understood from the complex organization
of the VDR gene (see Fig. 2), the identification of these
functional polymorphisms in the VDR gene is a challeng-
ing enterprise. While these results are still eagerly awaited,
several investigators have—nevertheless—over the past
years, analysed multiple bioresponse parameters using
the anonymous polymorphisms, including the BsmI RFLP,
Bsm–Apa–Taq haplotypes, and the polyA VNTR in the
3VUTR. These studies include in vitro cell biological and
molecular biological studies, but also in vivo measure-
ments of biochemical markers, and response to treatments
with vitamin D, calcium, and even hormone replacement
therapy (HRT) or bisphosphonates. In Fig. 4, a schematic
representation is shown of how functionality of polymor-
phisms can be tested at different levels, i.e., at the mRNA
level, the protein level, the cell level, etc. In the optimal
situation, the polymorphism is expected to show similar
directions of the allelic effects at all these levels and thus
allow to connect mechanisms at the molecular level with
epidemiological findings at the population level. For the
Cdx2 and the FokI polymorphism, this has now indeed
been established to a large extent, while for the BsmI–
ApaI–TaqI RFLPs and the polyA VNTR polymorphism,
this is less certain and controversy still exists. Although
one might argue that it is useless to perform any func-
tional study with an anonymous polymorphism, results
from such studies might still be informative because of the
(strong) LD that is present between the marker polymor-
phisms and the truly functional polymorphism. An over-view of the functional studies for each of these VDR
polymorphisms is presented in Tables 2A–C and these are
discussed below.
6.1. Cdx2 polymorphism
The Cdx2 polymorphism has been well characterized by
the studies of Arai et al. (2001) and Yamamoto et al.
(1999). The G to A polymorphism is located in a Cdx2
binding site in the 1e promoter region, and this site is
suggested to play an important role in intestinal-specific
transcription of the VDR gene. As the intestine is the
predominant area for calcium absorption, the Cdx2 site is
thought to influence the vitamin D regulation of calcium
absorption. The A allele has been demonstrated to be more
‘‘active’’ than the G-allele by binding the Cdx2 transcrip-
tion factor more strongly and by having more transcrip-
tional activity (Arai et al., 2001). Thus, the A allele is
thought to cause increased VDR expression in the intestine
and, thereby, can increase the transcription of calcium
transport proteins (such as calbindin 9K and  28K,
TRPV5, TRPV6). This could thereby enhance the intesti-
nal absorption of calcium and, thereby, to result in in-
creased BMD. Although this increased BMD has indeed
been demonstrated for Japanese women who carry the A
allele (Arai et al., 2001), this was not found in Caucasian
women (Fang et al., 2003). Yet, the A allele of this
polymorphism was indeed found to be associated with
decreased fracture risk (as would be expected from having
an increased BMD) in a large study of Caucasian women,
but independently of BMD (Fang et al., 2003). Although
the functionality of this polymorphism has indeed been
Table 2A
Functional effects of VDR polymorphisms: in vitro studies
Polymorphism Refs. Cell type Allelic differences Mechanism
VDR
expression
VDR mRNA
stability
Transactivation
by VDR
Cell growth
inhibition
Cdx2; A to G (Yamamoto
et al., 1999)
Caco-2 intestinal cell line A>G – A>G The G allele
diminished Cdx2
transcription factor
binding
FokI; C (F; 424
aa; M4) to T
(f; 427 aa; M1)
(Arai et al., 1997) Hela cell line – – 424 aa>427 aa –
(Gross et al., 1998a) GMK-Cos7 ND – ND –
Human fibroblasts ND – ND –
(Correa et al., 1999) Parathyroid adenomas ND – – –
(Jurutka et al., 2000) COS7, Hela, ROS 2/3 ND – 424 aa>427 aa – The 424 aa VDR (M4)
interacts more efficiently
with transcription factor
TFIIB
(Whitfield et al., 2001) Human
fibroblasts (n= 20)
– – 424 aa>427 aa –
(Colin et al., 2000) Human PBMC (n= 72) – – – 424
aa>427 aa
Bsm, Apa, Taq,
UTR (polyA
VNTR)
(Morrison et al., 1994) GMK Cos-7 BAt>baT – – – mRNA stability
of BAt is larger
than that of baT?
ROS 17/2.8 BAt>baT – – –
(Whitfield et al., 2001) GMK Cos-7 ND ND – –
Human osteoblast baT>BAt baT>BAt – –
(Durrin et al., 1999) Mouse NIH3T3 cells ND ND – –
(Crofts et al., 1996) Human fibroplast (n=9)
PBL (n= 13)
(ba)T>(BA)t – – –
(Gross et al., 1998b) Human
fibroblasts (n= 9)
ND – ND –
(Whitfield et al., 2001) Human fibroblasts
(n= 11)
– – L>S (baT>BAt) –
(Yamagata et al., 1999) Human PBMC
(n= 24; Japanese)
(BA)t>(ba)T – – –
(Mocharla et al., 1997) Human PBMC (n= 38) ND – – –
(Colin et al., 2000) Human PBMC (n= 72) – – – ND
(Verbeek et al., 1997) Human PBL, leukemia
cell line, prostate
cell line
(ba)T>(BA)t ND – –
(Carling et al.,
1997, 1998)
Human parathyroid
adenomas (n= 42)
BAt>baT – – BAt>baT
(Ohtera et al., 2001) Human osteoblasts
(n= 18; Japanese)
– – baT>BAt –
GMK=green monkey kidney; PBMC= peripheral blood mononuclear cells; PBL= peripheral blood lymphocytes; – = not analysed; ND= no difference.
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the A allele would confer lower risk for fracture has not
been elucidated yet and requires further study.
6.2. FokI polymorphism
From the genetic perspective, it is important to note that
the FokI RFLP can be considered an independent marker in
the VDR gene since there is no LD with any of the other
VDR polymorphisms and the LD area surrounding this
polymorphism seems to be very small (Fang et al., manu-
script in preparation). Therefore, LD with another polymor-
phism is not a likely explanation for the associationsobserved with this polymorphism, and so functional studies
should be focussed on the polymorphism itself. In a study
by Arai et al. (1997), evidence for the functionality of the
FokI polymorphism was obtained. Results from transcrip-
tional activation studies in transfected HeLa cells using a
reporter construct under the control of a short portion of the
rat 24-hydroxylase gene promoter region ( 291– + 9)
containing a vitamin D responsive element (VDRE) sug-
gested the short 424 amino acid VDR protein variant
(corresponding with the C-allele or ‘‘big F’’ allele) to be
more active than the long 427 aa variant, with a 1.7-fold
difference between the two variants. Gross et al. (1998a)
were not able to confirm these results. They also analysed
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acteristics of the VDR protein, but now in COS7 cells and
using the rat 24-hydroxylase promoter, although containing
a slightly larger region of the promoter ( 1399– + 76). In
addition, they analysed VDREs from the human osteocalcin
gene and the rat osteopontin gene but could not see FokI
allelic differences in these systems. Yet, the authors noted
that it might be difficult to observe the relatively small
effects of this polymorphism in these test systems. More-
over, small differences in cell type, promoter area, and gene
specificity of the VDRE might be crucial to see an allelic
difference. Jurutka et al. (2000) demonstrated the 424 aa
VDR variant to interact more efficiently with the transcrip-
tion factor TFIIB, using reporter constructs containing 1100
bp of a rat osteocalcin promoter in COS7-, HeLa, and ROS2/
3 cells. The authors concluded the 424 aa short VDR variant
to represent a more transcriptionally potent VDR protein.
This notion was corroborated by the same authors in the
analysis of 20 fibroblast cell lines of different endogenous
FokI VDR genotype using a reporter construct containing
four copies of the rat osteocalcin gene (Jurutka et al., 2000).
Results from our own laboratory (Colin et al., 2000) seem to
confirm the higher activity of the 424 aa short VDR variant
while using a different readout of functionality. We tested
capacity for growth inhibition by vitamin D in peripheral
blood mononuclear cells (PBMCs) of different genotype for
the FokI RFLP in cells derived from 72 postmenopausal
women (Colin et al., 2000). We observed that the PBMCs
carrying the ‘‘F’’ allele (corresponding to the 424 aa short
variant) had a lower ED50 and thus had a more active VDR
variant in inhibiting the (PHA-induced) cell growth.
In conclusion, we can state that the FokI polymorphism
seems to be functional and that the 424 aa VDR variant is
somewhat more active than the 427 aa variant in terms of its
transactivation capacity as a transcription factor. There
might be a gene-specific effect in that some promoter areas
of vitamin D target genes might be more sensitive to this
VDR genotype-dependent difference in activity, while
others may not. Together with cell-type-specific interaction
with co-transcription factors, this might result in a cell-type-
specific and organ-specific expression of the genotype-
dependent differences.
6.3. Bsm–Apa–Taq and 3VUTR polymorphisms
Most efforts to identify functional sequence variations in
the VDR gene have been focussed on the 3V regulatory
region because this is close to the anonymous markers used
mostly so far in association studies (see Figs. 2 and 3).
While the BsmI, ApaI, and TaqI RFLPs are located near the
3V end of the gene, the LD extends into the 3V regulatory
region containing the UTR. We already saw that the 3VUTR
of the VDR gene contains many polymorphisms and thus,
through the strong LD, these might explain associations
observed with Bsm–Apa and/or Taq RFLPs. The 3VUTR of
genes is known to be involved in regulation of expression,especially through regulation of mRNA stability, including
for steroid receptors which contain extensive 3VUTRs, such
as the glucocorticoid receptor alpha (Decker and Parker,
1995). For the latter, receptor polymorphisms in the 3VUTR
have been described in the so-called AUUUA-motifs which
influence the mRNA stability (Schaaf and Cidlowski, 2002).
Morrison et al. provided evidence of differential lucifer-
ase activity for the two 3VUTR-variants that are linked to
the two most frequent haplotypes, i.e., ‘‘baT’’ (haplotype 1
according to Uitterlinden et al., 1996) and ‘‘BAt’’ (haplo-
type 2). Durrin et al. (1999) have shown certain parts of the
UTR, so-called destabilizing elements, to be involved in
determining stability of the VDR-mRNA. However, they did
not find the UTRs linked to either ‘‘baT’’ or ‘‘BAt’’ haplo-
type to differ with respect to mRNA stability (Durrin et al.
1999). They used heterologous constructs (human VDR-
UTR sequences coupled to a rabbit h-globin gene) and cell
types (mouse NIH3T3 cells) to test for functionality. Espe-
cially, since it is known that 3VUTRs display cell-type-
specific effects on mRNA stability, this could be important
in demonstrating functionality of sequence variations in the
UTR. Although it is assumed that mRNA stability differ-
ences might underlie the allelic differences, alternative
explanations should still be considered. Other studies have
analysed differences in expression levels according to the 3V
polymorphisms, and although there is a tendency for the BAt
haplotype to display overall somewhat higher levels of
mRNA expression than baT, the results have not been
consistent (see Table 2A).
Recently, Whitfield et al. (2001) demonstrated functional
significance of the translation initiation codon polymor-
phism (detected as FokI RFLP) and the poly(A) stretch in
the 3VUTR. In a series of 20 fibroblast cell lines of different
VDR genotype, the relative transcription efficiency of the
endogenous VDR protein which was differing by the
genotype at both the FokI RFLP (F and f alleles) and the
poly(A) stretch with long (L) and short (S) alleles was
measured. The endogenous VDR protein is then acting as a
transcription factor for a 1,25-dihydroxyvitamin D3-respon-
sive reporter gene (containing the rat osteocalcin gene
VDRE) which is transfected in the cell. This study provided
evidence for so-called high (of the ‘‘FL’’ genotype) and low
(of the ‘‘fS’’ genotype) VDR activity. One of the possible
explanations mentioned included differences in translational
activity (rather than mRNA stability) of the different
mRNA-3VUTR variants. However, further research is nec-
essary to prove that assumption. In any case, this study also
illustrated the importance of analysing multiple polymor-
phisms in the VDR gene in relation to each other (as is
illustrated in Fig. 5; see below).
At another level, the responses by VDR genotype have
been analysed as differences in serum markers (Table 2B).
VDR is then thought to act on vitamin D responsive genes,
e.g., through gene-specific VDREs, which results in certain
protein/protein fragments being excreted into the circula-
tion. These 17 studies include several different serum
Fig. 5. The importance of gene-wide haplotypes in the VDR gene. Three adjacent SNPs in different parts of the VDR gene are shown for two individuals (A
and B indicated at the bottom). The subjects A and B have identical genotypes, i.e., they are both heterozygous for all three SNPs. However, they have different
haplotype combinations: 1 + 2 for subject A and 3 + 4 for subject B. The promoter area regulates production of mRNA, while the 3VUTR is involved in
stability/degradation of mRNA, and their interaction/combined effects regulates the net availability of the mRNA for translation into the VDR protein. In this
case, the example is shown for the Cdx2 promoter polymorphism which has two alleles A and G, of which the A allele is the more active variant in intestinal
cells. For the 3VUTR, the two different variants, haplotype 1 and haplotype 2, are presented consisting of haplotypes of the Bsm–Apa–Taq RFLPs. The
haplotype 1 is supposedly the more active/less unstable 3VUTR resulting in more VDR protein being produced. The VDR protein can occur in two variants:
‘‘little f’’ (less active, M1, 427 aa) and ‘‘big F’’ (more active, M4, 423 aa), and both A and B are heterozygous for this polymorphism. The result of the
particular haplotype combinations is that individual A has less of the ‘‘risk’’ VDR protein, i.e., the little f variant, M1, 427 aa long, than individual B in the
target cell. This could not have been predicted by analysing single SNPs and/or only looking at genotypes of individual SNPs, but is only evident upon analysis
of the gene-wide haplotypes.
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cin and PTH. In particular, osteocalcin has been analysed
because this is a highly vitamin-D-responsive gene and it is
frequently measured in clinical practice to monitor bone
metabolism (for bone formation activity). Although 7 (out
of 17) studies were not able to detect genotype-dependent
differences in serum levels of osteocalcin (or other bone
markers), 8 studies reported individuals with the BAt
haplotype to have higher osteocalcin levels than those with
the baT haplotype, while 3 (out of 17) studies observed an
opposite trend.
A similar pattern can be distinguished when we
analyse the studies which determined the in vivo response
to treatment by VDR genotype (Table 2C). Studies
included the analysis of response to treatment with
calcitriol, calcium, corticosteroids, HRT, and etidronate
and responses mostly involved measuring changes inBMD. Four out of nine studies reported the response
for BAt to be better than for baT. However, three out of
nine showed the opposite effect while three showed no
effect. Complicating factors to interpret these studies are
of course the different endpoints being measured and the
different polymorphisms in usually (and understandably)
small studies most likely lacking power to demonstrate
subtle effects.
Thus, when we overlook Tables 2A–C, the picture is still
complicated, but there seems to be a trend for the BAt-
haplotype (linked to short polyA VNTR alleles in the
3VUTR) to display somewhat better responses than the
baT-haplotype (linked to long polyA VNTR alleles). To-
gether with the in vitro studies, there is therefore some
argument to state that it might indeed be haplotype 2 (BAt)
which—in general—confers a better response than haplo-
type 1 (baT). It is tempting to speculate that perhaps this is
Table 2B
Functional effects of VDR polymorphisms: in vivo studiesa
Polymorphism Refs. Marker Allelic effect: serum concentration
Bsm, Apa, EcoRV (Morrison et al., 1992) Osteocalcin (n= 91) BA(t)>ba(T)
Bsm (Morrison et al., 1994) Calcitriol (n= 117) B(At)>b(aT)
Bsm (Kroger et al., 1995) Osteocalcin, ICTP (n= 23) b(aT)>B(At)
Bsm (Fleet et al., 1995) Osteocalcin, calcitriol (n= 154) ND
Bsm Apa Taq (Garnero et al., 1995) Osteocalcin, 25(OH), etc. (n= 189) B(At)>b(aT) : NS trendb
Bsm (Krall et al., 1995) 1,25 (OH)2D (n= 229) ND
Bsm (Howard et al., 1995) Osteocalcin, calcitriol, ICTP (n= 21) B(At)>b(aT)
Bsm Apa Taq (Tokita et al., 1996) Osteocalcin, BAP, 1,25 (OH)2D
(n= 159; Japanese)
BAt>baT
Bsm Apa Taq (Tsai et al., 1996) Osteocalcin, BAP, PICP, NTX
(n= 268; Chinese)
ND
Bsm (Mocharla et al., 1997) Osteocalcin, calcitriol (n= 38) ND
Bsm (Rauch et al., 1997) Osteocalcin, AlkPhosp, PICP (n= 50) B(At)>b(aT): NS trend
Bsm Apa Taq (McClure et al., 1997) Osteocalcin, calcitriol, PTH (n= 103) BAt>baT: NS trend for PTH, calcitriol
baT>BAt: NS trend for osteocalcin
Bsm (Graafmans et al., 1997) Osteocalcin, calcitriol ND
Bsm (Hansen et al., 1998) Osteocalcin, 25(OH), BAP (n= 200) ND
Bsm, FokI (Sowers et al., 1999;
Willing et al., 1998)
Osteocalcin, PTH, 25(OH)
(n= 372; n= 261)
ND
Bsm (Ferrari et al., 1999) Osteocalcin, PTH
(n= 72 young men)
B(At)>b(aT)
Bsm Apa Taq (Bell et al., 2001) Osteocalcin, PTH, 1,25
(OH)2D (n= 39 African
men, n= 44 Caucasian men)
(b)a(T)>(B)A(t) for PICP
a Studies used either one or all of the 3V polymorphisms, i.e., BsmI, ApaI, EcoRV, and TaqI. To relate these results to what is described in this chapter for
sequence variation at the 3V end of the VDR gene, the genotypes and allelic effects are presented as haplotypes 1 (baT) or 2 (BAt). Letters in brackets refer to
polymorphisms not actually tested in the study but inferred by this author based on VDR haplotype structure in the 3V area. All studies are in Caucasians unless
stated otherwise.
b NS trend: nonsignificant trend; ND= no difference.
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would theoretically result in higher numbers of VDR being
present in the target cell and thus giving this target cell a
better response to vitamin D.
In view of what has been discussed above, it is not very
surprising that these ‘‘functional’’ studies have shown alleles
of only few polymorphisms being consistently associated
with all of the different parameters of functionality such as
displayed in Fig. 4. This holds true for the FokI polymor-
phism and the Cdx2 polymorphism. Yet, the studies of the 3V
polymorphisms have been hampered. Major caveats of theseTable 2C
Functional effects of VDR polymorphisms: in vivo studies of response to treatme
Polymorphism Refs. Treatment
Bsm (Howard et al., 1995) 7 days calcitri
Bsm Apa Taq (Matsuyama et al., 1995) 12 months 1alp
Bsm (Graafmans et al., 1997) 2 years calcitr
Bsm (Krall et al., 1995) 2 years calciu
Bsm (Deng et al., 1998) 3.5 years HRT
Apa Taq (Kurabayashi et al., 1999) 1 year HRT (n
Bsm Taq (Ho et al., 1999) >1 year cortico
Bsm (Marc et al., 1999) 1 year etidron
FokI (Kurabayashi et al., 1999) 1 year HRT (n
ND=no difference.studies are (a) the use of the anonymous rather than
functional polymorphisms to group subjects and cells by
genotype and (b) the use of different types of bioresponses
and different cell types and cell culture conditions in which
the vitamin D response might not be evident under the
conditions of the experiment. Therefore, the identification of
truly functional polymorphisms in the 3VUTR and the use of
different well-defined cell types will help in clarifying the
molecular mechanisms underlying the associations observed
especially for the 3V polymorphisms such as BsmI, ApaI,
and TaqI.nt
Response
Serum markers BMD
ol (n= 21) b(aT)>B(At) –
haOH-D3 (n= 115) – baT>BAt
iol (n= 81) ND B(At)>b(aT)
m (n= 229) – B(At)>b(aT)
(n= 108) – B(aT)>B(At)
= 82) – (ba)T>(BA)t
steroids (n= 263) – ND
ate (n= 24) – B(At)>b(aT)
= 82) – ND
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VDR polymorphisms and their interrelationships in such
experiments since they will interact with each other to
determine VDR expression and activity (see Fig. 5). This
was already indicated by the work of Whitfield et al. (2001)
and this is further illustrated in Fig. 5 where the interaction
of promoter-, coding-, and 3VUTR-polymorphisms is high-
lighted. In a normally active cell, certain promoter poly-
morphisms will ‘‘join forces’’ with certain 3VUTR
polymorphisms in regulating the amount of VDR mRNA
being available in a certain target cell. Together, they
determine the expression of the known FokI variants, F
and f, which are the (functionally different) VDR proteins
that act, for example, on VDREs to activate certain vitamin
D responsive genes to be expressed. In the example, sub-
jects A and B have identical genotypes at three polymor-
phisms (the Cdx2, the FokI, and the Bsm–Apa–Taq 3VUTR
polymorphisms) but only differ in their particular combina-
tions of alleles on chromosomes (i.e., their haplotypes). This
ultimately results in less ‘‘high-activity’’ VDR proteins (i.e.,
having the ‘‘F’’ allele) being expressed in cells of subject B,
which is then expected to display lower responses to vitamin
D. In this case, the Cdx2 promoter variant is involved and
differences between subjects are then expected at the level
of calcium absorption in intestinal cells. However, when
only one of the polymorphisms would have been tested in
cell biological experiments, this would not have been
detected (unless very large genotype groups would have
been analysed to detect the individual subtle differences).
Moreover, when only the three individual polymorphisms
would have been analysed and the haplotypes would not
have been taken into account, these effects would also not
have been noticed. Thus, not controlling for the underlying
complexities in VDR polymorphisms, i.e., by not analysing
multiple polymorphisms and analysing their haplotypes, can
also help to explain contradictory results from in vitro and in
vivo functional experiments.7. Conclusion
Since the first publications on polymorphisms in the
VDR in 1992, considerable progress has been made in
unraveling the VDR in genetic terms as exemplified by
the elucidation of the genomic localization, structure, and
polymorphisms. A next important phase that is currently
in progress and which is strongly facilitated by the data
from the Human Genome Project is the establishment of
LD and construction of haplotype maps. A most chal-
lenging and demanding area is the assessment of con-
sequences of polymorphisms for the VDR function. First
small steps have been made to address this issue, but an
important progress is needed, which may find its basis in
a synergy between the ongoing genetic analysis of the
VDR and the increasing knowledge on molecular mech-
anisms and cellular specificity of vitamin D action.Knowledge of the molecular and functional consequences
of the VDR polymorphisms is crucial to fully appreciate
their significance and understand their potential clinical
implications.References
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